Popular GLP-1 weight loss drugs could soon be available for pets. Okava Pharmaceuticals, based in San Francisco, just launched MEOW-1 — a clinical study that utilizes a tiny, under-the skin implant in 50 cats to release a GLP-1 medication drug over six months. The implant, called OKV-119, "is designed to mimic many of the physiological effects of fasting — improved insulin sensitivity, reduced fat mass, and more efficient energy metabolism — without requiring significant changes in feeding